retatrutide expanded access program How to Get in 2026 Eli Lilly gave extraordinary obesity

References References Agnew, R (Jan 2013) 'Benjamin Moore FRS (1867-1922)', Ulster Medical Journal , 82/1, 131-4

Larger Phase 3 trials are underway to confirm the long-term safety and benefits before the medication can be considered for approval

Dysesthesia: A New Safety Signal The TRIUMPH 4 trial revealed dysesthesia as a notable side effect that distinguishes Retatrutide from other GLP 1 medications

This shift does not diminish the importance of safety, but it underscores the need to evaluate peptide systems within an appropriate therapeutic context rather than through overly conservative early-stage filters

2020;105(4):dgaa061

Assessment report for GLP-1 based therapies (Article 53 procedure)